Horizon Pharma Announces Second Quarter 2012 Financial Results

Horizon Pharma Announces Second Quarter 2012 Financial Results and
Provides Business Update 
Conference Call and Webcast Today, August 10th, at 8:00 a.m. ET 
DEERFIELD, IL -- (Marketwire) -- 08/10/12 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) today provided an update on the Company's business and
announced financial results for the second quarter and six months
ended June 30, 2012. 
DUEXIS(R) Highlights 


 
--  Gross sales of DUEXIS in the second quarter of 2012 increased 91%
    compared to the first quarter of 2012.
--  Expansion of the Company's field sales force from 80 initial
    representatives to 150 representatives is ongoing and expected to be
    completed in the third quarter of 2012, and together with the recent
    signing of the Mallinckrodt co-promotion agreement puts the Company on
    target to increase physicians called upon five-fold in the fourth
    quarter of 2012 compared to the first half of 2012.
--  According to monthly data from Source Healthcare Analytics (SHA),
    formerly Wolters Kluwer, total prescriptions for the second quarter of
    2012 were 18,805, an increase of 81% over prescriptions for the first
    quarter of 2012.
--  4,028 cumulative DUEXIS prescribers through June 30, 2012,
    representing an increase of 75% versus March 31, 2012, and the
    addition of over 100 new prescribers each week during the second
    quarter of 2012. Representative prescriptions generated per detail
    also increased 150% in the second quarter vs. the first quarter of
    2012.
--  In June, the Company entered into a collaboration, license and supply
    agreement with Gruenenthal S.A. for the commercialization of
    DUEXIS in Latin America.
--  Anticipated decision on DUEXIS MAA expected in fourth quarter of 2012.

  
RAYOS(R) Highlights 


 
--  RAYOS (prednisone) delayed release tablets, approved by the FDA on
    July 26, 2012 to treat a broad range of diseases including rheumatoid
    arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis
    (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive
    pulmonary disease (COPD).
--  Initial focus will be on the launch of RAYOS in rheumatologic diseases
    such as rheumatoid arthritis and PMR in the fourth quarter of 2012.
--  Based on the extent of the approved indications, the Company will be
    developing a broader commercial strategy to expand the opportunity for
    RAYOS in key IL-6 mediated diseases, including asthma and COPD.

  
Other Recent Highlights 


 
--  Named Michael Grey as lead independent director.
--  Promoted Todd N. Smith to executive vice president and chief
    commercial officer.
--  Hired Jeff Kent, M.D. as senior vice president, medical affairs and
    outcomes research. Dr. Kent was formerly head of global medical
    affairs for HUMIRA at Abbott.

  
"With our ongoing sales force expansion and recent DUEXIS U.S.
co-promotion agreement with Mallinckrodt, which together are expected
to increase the number of called upon physicians from 10,000 to
50,000, and our U.S. approval of RAYOS, we are well positioned to
successfully drive near-term revenue for the Company," said Timothy
P. Walbert, chairman, president and chief executive officer, Horizon
Pharma. "In addition to driving the uptake of DUEXIS after our recent
product launch, we received FDA approval for RAYOS in July for
multiple indications, including RA and polymyalgia rheumatica and we
plan on launching RAYOS in the fourth quarter this year." 
Second Quarter Financial Results 
For the second quarter ended June 30, 2012, gross and net sales were
$4.6 million and $3.8 million, respectively, compared to $1.3 million
in gross and net sales for the second quarter of 2011. DUEXIS gross
sales were $2.1 million and net sales were $1.6 million after
deducting trade discounts and allowances of $0.2 million and co-pay
assistance costs of $0.3 million, and represented 45% of gross sales
and 41% of net sales during the quarter ended June 30, 2012. Gross
and net sales for LODOTRA increased 90% and 71%, respectively, during
the second quarter of 2012 compared to the same period in the prior
year as a result of higher product shipments to the Company's
distribution partner, Mundipharma. The Company has determined that
shipment of DUEXIS to wholesale distributors and retail chains does
not currently meet the criteria for revenue recognition at the time
of shipment which requires a reliable estimate of returns based on
history and therefore continues to defer DUEXIS revenue recognition
until the right of return no longer exists, which is the earlier of
DUEXIS being dispensed through patient prescriptions or the
expiration of the right of return. As of June 30, 2012, the Company
had $1.3 million in deferred revenue on its balance sheet related to
DUEXIS shipments. 
Net loss for the quarter ended June 30, 2012, was $22.8 million, or
$0.68 per share based on 33,715,703 weighted average shares
outstanding, compared to a net loss of $11.6 million, or $7.78 per
share in the quarter ended June 30, 2011 based on 1,496,278 weighted
average shares outstanding. Non-GAAP net loss for the quarter ended
June 30, 2012, was $20.6 million, or $0.62 per share, compared to
non-GAAP net loss of $8.0 million, or $5.35 per share in the second
quarter of 2011. Horizon provides non-GAAP financial measures, which
it believes can enhance an overall understanding of Horizon's
financial performance when considered together with GAAP figures.
Refer to the section of this press release below entitled "Note
Regarding Use of Non-GAAP Financial Measures" for a full discussion
on this subject. The Company had cash and cash equivalents of $63.5
million at June 30, 2012.  
Research and development expenses increased $0.7 million, from $3.5
million during the three months ended June 30, 2011, to $4.2 million
during the three months ended June 30, 2012, primarily associated
with a $0.6 million increase in medical education and related grants. 
Sales and marketing expenses increased $9.3 million, from $1.2
million during the three months ended June 30, 2011, to $10.5 million
during the three months ended June 30, 2012. The increase in expense
was primarily attributable to ongoing sales and promotional efforts
related to our DUEXIS product launch, including a $4.6 million
increase in salaries and benefits expense associated with additional
staffing of our sales and marketing functions, a $2.3 million
increase in market research and marketing programs, a $1.4 million
increase in consulting and outside service costs and a $0.8 million
increase in samples and marketing materials. 
General and administrative expenses increased $1.3 million, from $3.3
million during the three months ended June 30, 2011, to $4.6 million
during the three months ended June 30, 2012, primarily due to a $0.7
million increase in stock-based compensation expense, a $0.4 million
increase in salaries and benefits expense associated with an increase
in administrative personnel, a $0.3 million increase in legal costs
associated with intellectual property related matters and public
company compliance fees and $0.2 million in higher rent and insurance
costs, partially offset by a reduction in consulting expenses during
the current quarter. 
Interest expense, net was $3.2 million for the three months ended
both June 30, 2012 and 2011, respectively. Interest expense during
the current quarter was primarily the result of higher borrowing
balances under our current senior secured loan, partially offset by
the absence of debt extinguishment costs in the current quarter.
During the three months ended June 30, 2011, the Company incurred
$1.9 million of interest expense related to extinguishment of the
Kreos and Silicon Valley Bank facilities.  
Foreign exchange loss was $1.4 million for the quarter ended June 30,
2012, compared to a foreign exchange gain of $0.1 million during the
three months ended June 30, 2011. The foreign exchange loss during
the second quarter of 2012 was associated with a decline in the value
of the Euro against the U.S. dollar during the three months ended
June 30, 2012, which resulted in an unfavorable currency impact for
our Horizon Pharma AG subsidiary. 
Year-to-Date Financial Results 
For the six months ended June 30, 2012, gross and net sales were $7.5
million and $6.4 million, respectively, compared to $3.1 million in
gross and net sales for the six months ended June 30, 2011. DUEXIS
gross sales were $3.2 million and net sales were $2.5 million after
deducting trade discounts and allowances of $0.3 million and co-pay
assistance costs of $0.4 million, and represented 43% of gross sales
and 39% of net sales during the six months ended June 30, 2012. Gross
and net sales for LODOTRA increased 39% and 26%, respectively, during
the six months ended June 30, 2012 compared to the same period in the
prior year as a result of higher product shipments to the Company's
distribution partner, Mundipharma. Net loss for the six months ended
June 30, 2012, was $46.5 million, or $1.61 per share based on
28,909,080 weighted average shares outstanding, compared to a net
loss of $19.3 million, or $12.91 per share based on 1,495,126
weighted average shares outstanding, during the six months ended June
30, 2011. Non-GAAP net loss for the six months ended June 30, 2012,
was $41.2 million, or $1.43 per share, compared to non-GAAP net loss
of $14.0 million, or $9.38 per share, during the six months of 2011.  
Research and development expenses increased $2.1 million, from $6.2
million during the six months ended June 30, 2011, to $8.3 million
during the six months ended June 30, 2012. The increase in research
and development expense was primarily associated with a $2.1 million
increase in salaries and benefits expense in support of our RAYOS new
drug application and expenses associated with DUEXIS clinical
studies. 
Sales and marketing expenses increased $19.2 million, from $2.3
million during the six months ended June 30, 2011, to $21.5 million
during the six months ended June 30, 2012, which was primarily
attributable to initial staffing of our sales and marketing functions
during the fourth quarter of 2011, resulting in $10.7 million in
higher salaries and benefits expense. In addition, primarily as a
result of ongoing sales and promotional efforts for our DUEXIS
product launch, during the six months ended June 30, 2012,
advertising and promotional efforts increased $4.9 million, samples
and marketing expenses increased $1.2 million, market research
expenses increased $1.0 million and consulting fees increased $0.8
million. 
General and administrative expenses increased $3.4 million, from $6.4
million during the six months ended June 30, 2011, to $9.8 million
during the six months ended June 30, 2012, primarily due to a $1.5
million increase in salaries and benefits expense associated with an
increase in administrative personnel, $0.9 million in higher legal
and consulting costs associated with intellectual property related
matters and public company compliance costs and a $0.3 million
increase in insurance and rent expense. 
Interest expense, net increased $3.2 million, from $4.5 million
during the six months ended June 30, 2011, to $7.7 million during the
six months ended June 30, 2012. The increase in interest expense was
primarily attributable to incremental interest expense associated
with higher borrowing balances under our senior secured loan facility
and higher debt extinguishment costs. During the six months ended
June 30, 2011, there was a $1.9 million charge related to the loss on
debt extinguishment of the Kreos and Silicon Valley Bank facilities
compared to a $2.5 million charge related to our extinguishment of
the Oxford and Kreos debt facilities during the six months ended June
30, 2012.  
Foreign exchange loss was $0.9 million during the six months ended
June 30, 2012, compared to a foreign exchange gain of $0.5 million
during the six months ended June 30, 2011. The foreign exchange loss
reported was associated with a continuing decline in the value of the
Euro against the U.S. dollar during the current year, which resulted
in an unfavorable currency impact for our Horizon Pharma AG
subsidiary, compared to a gain in the Euro versus the U.S. dollar
during the corresponding period in 2011. 
Note Regarding Use of Non-GAAP Financial Measures 
Horizon provides non-GAAP net income (loss) and net income (loss) per
share financial measures that include adjustments to GAAP figures.
These adjustments to GAAP exclude non-cash items such as stock
compensation and depreciation and amortization, and other non-cash
charges. Horizon believes that these non-GAAP financial measures,
when considered together with the GAAP figures, can enhance an
overall understanding of Horizon's financial performance. The
non-GAAP financial measures are included with the intent of providing
investors with a more complete understanding of operational results
and trends. In addition, these non-GAAP financial measures are among
the indicators Horizon's management uses for planning and forecasting
purposes and measuring the Company's performance. These non-GAAP
financial measures should be considered in addition to, and not as a
substitute for, or superior to, financial measures calculated in
accordance with GAAP. The non-GAAP financial measures used by the
Company may be calculated differently from, and therefore may not be
comparable to, non-GAAP financial measures used by other companies.
Please refer to the financial statements portion of this press
release for a reconciliation of these non-GAAP financial measures to
the comparable GAAP financial measures. 
Conference Call 
At 8:00 am Eastern Time today, Horizon's management will host a live
conference call and webcast to review the Company's financial and
operating results and provide a general business update.  
The live webcast and a replay may be accessed by visiting Horizon's
website at http://ir.horizon-pharma.com. Please connect to the
Company's website at least 15 minutes prior to the live webcast to
ensure adequate time for any software download that may be needed to
access the webcast. Alternatively, please call 1-888-338-8373 (U.S.)
or 973-872-3000 (international) to listen to the conference call. The
conference ID number for the live call is 96271110. Telephone replay
will be available approximately two hours after the call. To access
the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406
(international). The conference ID number for the replay is 96271110. 
About Horizon Pharma 
Horizon Pharma, Inc. is a biopharmaceutical company that is
developing and commercializing innovative medicines to target unmet
therapeutic needs in arthritis, pain and inflammatory diseases. For
more information, please visit www.horizonpharma.com. 
Forward-Looking Statements 
This press release contains forward-looking statements, including
statements regarding the on-going commercial launch of DUEXIS, the
planned expansion of the Company's field sales force, the pursuit of
regulatory approval for DUEXIS in Europe, development of commercial
strategies to expand the opportunity for RAYOS in key IL-6 mediated
diseases, and the expected timeline for commercial launch of RAYOS in
the United States. These forward-looking statements are based on
management's expectations and assumptions as of the date of this
press release, and actual results may differ materially from those in
these forward-looking statements as a result of various factors.
These factors include, but are not limited to, risks regarding
Horizon's ability to commercialize products successfully, whether
initial commercial data regarding DUEXIS in the United States are
indicative of future results, Horizon's ability to successfully
recruit and retain additional sales and marketing personnel and to
successfully manage contract sales and marketing personnel, whether
DUEXIS will be approved for marketing in Europe, the potential for
delays in regulatory review of Horizon's applications for marketing
approval, Horizon's ability to comply with any post-approval
regulatory requirements, and the need to potentially obtain
additional financing even after the recently completed debt and
equity financings to successfully commercialize or further develop
DUEXIS and RAYOS/LODOTRA. For a further description of these and
other risks facing the Company, please see the risk factors described
in the Company's filings with the United States Securities and
Exchange Commission, including those factors discussed under the
caption "Risk Factors" in those filings. Forward-looking statements
speak only as of the date of this press release, and the Company
undertakes no obligation to update or revise these statements, except
as may be required by law. 


 
                                                                            
                            HORIZON PHARMA, INC.                            
                   CONDENSED CONSOLIDATED BALANCE SHEETS                    
              (in thousands, except share and per share data)               
                                                                            
                                                           As of            
                                               ---------------------------- 
                                                  June 30,     December 31, 
                                                    2012           2011     
                                               -------------  ------------- 
Assets                                                  (Unaudited)         
Current assets                                                              
  Cash and cash equivalents                    $      63,460  $      17,966 
  Restricted cash                                        750            750 
  Accounts receivable, net                         
      622          2,372 
  Inventories, net                                     3,157          1,195 
  Prepaid expenses and other current assets            4,401          2,763 
                                               -------------  ------------- 
    Total current assets                              72,390         25,046 
  Property and equipment, net                          3,804          3,245 
  Developed technology, net                           32,893         35,602 
  In-process research and development                 35,586         36,638 
  Other assets                                         4,079            547 
                                               -------------  ------------- 
    Total assets                               $     148,752  $     101,078 
                                               =============  ============= 
Liabilities and Stockholders' Equity                                        
Current liabilities                                                         
  Accounts payable                             $       7,890  $       8,170 
  Accrued expenses                                    11,149          8,926 
  Deferred revenues - current portion                  3,608          3,281 
  Notes payable - current portion                      3,978          3,604 
                                               -------------  ------------- 
    Total current liabilities                         26,625         23,981 
Long-term liabilities                                                       
  Notes payable, net of debt discount                 47,141         15,834 
  Deferred revenues, net of current                    8,044          5,666 
  Deferred tax liabilities, net                        8,948          9,561 
  Other long term liabilities                            121            124 
                                               -------------  ------------- 
    Total liabilities                                 90,879         55,166 
                                               -------------  ------------- 
                                                                            
Commitments and Contingencies                                               
                                                                            
Stockholders' equity                                                        
  Common stock, $0.0001 par value per share;                                
   200,000,000 shares authorized; 33,746,493                                
   and 19,627,744 shares issued and                                         
   outstanding at June 30, 2012 and December                                
   31, 2011 respectively.                                  3              2 
  Additional paid-in capital                         329,315        270,015 
  Accumulated other comprehensive loss                (4,620)        (3,788)
  Accumulated deficit                               (266,825)      (220,317)
                                               -------------  ------------- 
    Total stockholders' equity                        57,873         45,912 
                                               -------------  ------------- 
    Total liabilities and stockholders' equity $     148,752  $     101,078 
                                               =============  ============= 
                                                                            
                                                                            
                            HORIZON PHARMA, INC.                            
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS               
              (in thousands, except share and per share data)               
                                                                            
                             For the Three Months      For the Six Months   
                                    Ended                    Ended          
                                   June 30,                 June 30,        
                           -----------------------  ----------------------- 
                               2012        2011         2012        2011    
                           -----------  ----------  -----------  ---------- 
                                 (Unaudited)              (Unaudited)       
Revenues                                                                    
Sales of goods             $     4,556  $    1,294  $     7,411  $    3,057 
Contract revenue                    52          41          105          70 
                           -----------  ----------  -----------  ---------- 
    Gross sales                  4,608       1,335        7,516       3,127 
Sales discounts and                                                         
 allowances                       (767)          -       (1,152)          - 
                           -----------  ----------  -----------  ---------- 
    Net sales          
          3,841       1,335        6,364       3,127 
                           -----------  ----------  -----------  ---------- 
                                                                            
Cost of goods sold               2,855       2,104        4,922       3,943 
                           -----------  ----------  -----------  ---------- 
Gross profit (loss)                986        (769)       1,442        (816)
Operating Expenses                                                          
  Research and development       4,233       3,462        8,302       6,190 
  Sales and marketing           10,543       1,169       21,515       2,285 
  General and                                                               
   administrative                4,555       3,348        9,758       6,449 
                           -----------  ----------  -----------  ---------- 
    Total operating                                                         
     expenses                   19,331       7,979       39,575      14,924 
                           -----------  ----------  -----------  ---------- 
Operating loss                 (18,345)     (8,748)     (38,133)    (15,740)
                                                                            
Interest expense, net           (3,191)     (3,185)      (7,742)     (4,469)
Other expense                       (4)          -          (56)          - 
Foreign exchange (loss)                                                     
 gain                           (1,401)        110         (900)        532 
                           -----------  ----------  -----------  ---------- 
Loss before benefit for                                                     
 income taxes                  (22,941)    (11,823)     (46,831)    (19,677)
Income tax benefit                (159)       (186)        (323)       (368)
                           -----------  ----------  -----------  ---------- 
Net loss                   $   (22,782) $  (11,637) $   (46,508) $  (19,309)
                           ===========  ==========  ===========  ========== 
                                                                            
Net loss per share - basic                                                  
 and diluted               $     (0.68) $    (7.78) $     (1.61) $   (12.91)
                           -----------  ----------  -----------  ---------- 
Weighted average shares                                                     
 outstanding used in                                                        
 calculating net loss per                                                   
 share - basic and diluted  33,715,703   1,496,278   28,909,080   1,495,126 
                           -----------  ----------  -----------  ---------- 
                                                                            
                                                                            
                                                                            
                            HORIZON PHARMA, INC.                            
            RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET LOSS            
              (in thousands, except share and per share data)               
                                                                            
                           Three Months Ended June   Six Months Ended June  
                                     30,                      30,           
                           -----------------------  ----------------------- 
                               2012        2011         2012        2011    
                           -----------  ----------  -----------  ---------- 
                                 (Unaudited)              (Unaudited)       
                                                                            
GAAP Net Loss              $   (22,782) $  (11,637) $   (46,508) $  (19,309)
Non-GAAP Adjustments (net                                                   
 of tax effect):                                                            
  Amortization of                                                           
   developed technology            684         777        1,397       1,518 
  Stock-based compensation         731         628        2,490       1,225 
  Non-cash interest                                                         
   expense                         576       2,170        1,169       2,401 
  Depreciation expense             208         101          392         201 
  Amortization of deferred                                                  
   revenue                         (52)        (41)        (105)        (70)
                           -----------  ----------  -----------  ---------- 
    Total of non-GAAP                                                       
     adjustments                 2,147       3,635        5,343       5,275 
                           -----------  ----------  -----------  ---------- 
Non-GAAP Net Loss          $   (20,635) $   (8,002) $   (41,165) $  (14,034)
                           ===========  ==========  ===========  ========== 
                                                                            
Weighted average shares -                                                   
 basic and diluted          33,715,703   1,496,278   28,909,080   1,495,126 
                                                                            
GAAP net loss per common                                                    
 share - basic and diluted $     (0.68) $    (7.78) $     (1.61) $   (12.91)
  Non-GAAP adjustments                                                      
   detailed above                 0.06        2.43         0.18        3.53 
                           -----------  ----------  -----------  ---------- 
Non-GAAP net loss per                                                       
 common share - basic and                                                   
 diluted                   $     (0.62) $    (5.35) $     (1.43) $    (9.38)
                           ===========  ==========  ===========  ========== 
                                                                            
                                                                            
                                                                            
                            HORIZON PHARMA, INC.                            
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS               
                               (in thousands)                               
                                                                            
                                                  Six Months Ended June 30, 
                                                 -------------------------- 
                                                     2012          2011     
                                                 ------------  ------------ 
                                                         (Unaudited)        
Cash flows from operating activities                                        
Net loss                                         $    (46,508) $    (19,309)
Adjustments to reconcile net loss to net cash                               
 used in operating activities                                               
  Depreciation and amortization                         2,140         2,043 
  Stock-based compensation                              2,490         1,225 
  Non-cash interest expense                             1,169         2,401 
  Paid in kind interest expense                         1,079             - 
  Loss on disposal of assets                               68             - 
  Foreign exchange loss (gain)                            900          (532)
  Changes in operating assets and liabilities:                              
    Accounts receivable                                 1,751           595 
    Inventories, net     
                              (2,001)         (194)
    Prepaid expenses and other current assets          (1,631)          655 
    Accounts payable                                     (255)        2,456 
    Accrued expenses                                    1,527          (597)
    Deferred revenues                                   2,973           989 
    Deferred tax liabilities                             (349)         (378)
                                                 ------------  ------------ 
      Net cash used in operating activities           (36,647)      (10,646)
                                                 ------------  ------------ 
Cash flows from investing activities                                        
Purchase of property and equipment                     (1,043)          (36)
                                                 ------------  ------------ 
      Net cash used in investing activities            (1,043)          (36)
                                                 ------------  ------------ 
Cash flows from financing activities                                        
Proceeds from issuance of notes payable, net of                             
 issuance costs                                        55,578        16,651 
Repayment of notes payable                            (19,814)      (12,365)
Proceeds from private equity offering, net of                               
 offering costs                                        47,475             - 
Proceeds from the issuance of common stock                147             - 
Deferred financing expenses                                 -          (237)
Proceeds from issuance of bridge notes payable                              
 to related parties                                         -         6,766 
Proceeds from stock option exercises                        -            42 
                                                 ------------  ------------ 
      Net cash provided by financing activities        83,386        10,857 
                                                 ------------  ------------ 
Effect of exchange rate changes on cash and cash                            
 equivalents                                             (202)          213 
      Net increase in cash and cash equivalents        45,494           388 
Cash and cash equivalents                                                   
Beginning of period                                    17,966         5,384 
                                                 ------------  ------------ 
End of period                                    $     63,460  $      5,772 
                                                 ============  ============ 

  
Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
investor-relations@horizonpharma.com 
Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
kgalante@burnsmc.com 
Media 
Geoff Curtis 
DJE Science 
312-550-8138 
geoff.curtis@djescience.com